BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 23411111)

  • 1. Regulatory decisions on endocrine disrupting chemicals should be based on the principles of endocrinology.
    Vandenberg LN; Colborn T; Hayes TB; Heindel JJ; Jacobs DR; Lee DH; Myers JP; Shioda T; Soto AM; vom Saal FS; Welshons WV; Zoeller RT
    Reprod Toxicol; 2013 Jul; 38():1-15. PubMed ID: 23411111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fifteen years after "Wingspread"--environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go.
    Hotchkiss AK; Rider CV; Blystone CR; Wilson VS; Hartig PC; Ankley GT; Foster PM; Gray CL; Gray LE
    Toxicol Sci; 2008 Oct; 105(2):235-59. PubMed ID: 18281716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary.
    Beausoleil C; Ormsby JN; Gies A; Hass U; Heindel JJ; Holmer ML; Nielsen PJ; Munn S; Schoenfelder G
    Chemosphere; 2013 Oct; 93(6):847-56. PubMed ID: 23932820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why endocrine disrupting chemicals (EDCs) challenge traditional risk assessment and how to respond.
    Futran Fuhrman V; Tal A; Arnon S
    J Hazard Mater; 2015 Apr; 286():589-611. PubMed ID: 25646754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological issues in human studies of endocrine disrupting chemicals.
    Lee DH; Jacobs DR
    Rev Endocr Metab Disord; 2015 Dec; 16(4):289-97. PubMed ID: 26880303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing dose-response relationships for endocrine disrupting chemicals (EDCs): a focus on non-monotonicity.
    Zoeller RT; Vandenberg LN
    Environ Health; 2015 May; 14():42. PubMed ID: 25971795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of and Challenges in Regulating Endocrine Disruptors - How Regulators and Industry Can Conquer?
    Dhiman SK; Dureja H
    Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1664-1681. PubMed ID: 32504507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging the gap between academic research and regulatory health risk assessment of Endocrine Disrupting Chemicals.
    Beronius A; Hanberg A; Zilliacus J; Rudén C
    Curr Opin Pharmacol; 2014 Dec; 19():99-104. PubMed ID: 25238457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A curated knowledgebase on endocrine disrupting chemicals and their biological systems-level perturbations.
    Karthikeyan BS; Ravichandran J; Mohanraj K; Vivek-Ananth RP; Samal A
    Sci Total Environ; 2019 Nov; 692():281-296. PubMed ID: 31349169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose effects of hormones and endocrine disruptors.
    Vandenberg LN
    Vitam Horm; 2014; 94():129-65. PubMed ID: 24388189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals.
    Vandenberg LN; Ågerstrand M; Beronius A; Beausoleil C; Bergman Å; Bero LA; Bornehag CG; Boyer CS; Cooper GS; Cotgreave I; Gee D; Grandjean P; Guyton KZ; Hass U; Heindel JJ; Jobling S; Kidd KA; Kortenkamp A; Macleod MR; Martin OV; Norinder U; Scheringer M; Thayer KA; Toppari J; Whaley P; Woodruff TJ; Rudén C
    Environ Health; 2016 Jul; 15(1):74. PubMed ID: 27412149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using systematic reviews for hazard and risk assessment of endocrine disrupting chemicals.
    Beronius A; Vandenberg LN
    Rev Endocr Metab Disord; 2015 Dec; 16(4):273-87. PubMed ID: 26847432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A restatement of the natural science evidence base on the effects of endocrine disrupting chemicals on wildlife.
    Godfray HCJ; Stephens AEA; Jepson PD; Jobling S; Johnson AC; Matthiessen P; Sumpter JP; Tyler CR; McLean AR
    Proc Biol Sci; 2019 Feb; 286(1897):20182416. PubMed ID: 30963852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine disruptors: Challenges and future directions in epidemiologic research.
    Ho V; Pelland-St-Pierre L; Gravel S; Bouchard MF; Verner MA; Labrèche F
    Environ Res; 2022 Mar; 204(Pt A):111969. PubMed ID: 34461123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECETOC Florence workshop on risk assessment of endocrine substances, including the potency concept.
    Fegert I
    Toxicol Lett; 2013 Dec; 223(3):310-4. PubMed ID: 23558296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A path forward in the debate over health impacts of endocrine disrupting chemicals.
    Zoeller RT; Bergman Å; Becher G; Bjerregaard P; Bornman R; Brandt I; Iguchi T; Jobling S; Kidd KA; Kortenkamp A; Skakkebaek NE; Toppari J; Vandenberg LN
    Environ Health; 2014 Dec; 13():118. PubMed ID: 25533907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement.
    Solecki R; Kortenkamp A; Bergman Å; Chahoud I; Degen GH; Dietrich D; Greim H; Håkansson H; Hass U; Husoy T; Jacobs M; Jobling S; Mantovani A; Marx-Stoelting P; Piersma A; Ritz V; Slama R; Stahlmann R; van den Berg M; Zoeller RT; Boobis AR
    Arch Toxicol; 2017 Feb; 91(2):1001-1006. PubMed ID: 27714423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting report: international workshop on endocrine disruptors: exposure and potential impact on consumers health.
    Rousselle C; Ormsby JN; Schaefer B; Lampen A; Platzek T; Hirsch-Ernst K; Warholm M; Oskarsson A; Nielsen PJ; Holmer ML; Emond C
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):7-11. PubMed ID: 23211416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of research on endocrine disruption for the environmental risk assessment, regulation and monitoring of chemicals in the European Union.
    Matthiessen P; Johnson I
    Environ Pollut; 2007 Mar; 146(1):9-18. PubMed ID: 16996184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    Toxicol Lett; 2020 Oct; 331():259-264. PubMed ID: 32360654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.